Activity Assay Kits

ZediXclusive Microbial Transglutaminase Assay Kit

chromogenic, Hydroxamate

1 Kit 310 € available

Art. No. Z009
Background info Transglutaminases are a family of enzymes that catalyse the posttranslational modification of proteins by inserting an isopeptide bond within or between polypeptide chains (Folk, J. E. and Cole, P. W., 1966). These enzymes catalyse the acyl transfer reaction between the γ-carboxyamide group of peptide-bound glutamine residues and a variety of primary amines, particularly the ε-amino group of lysine (Lorand L. et al., 1962). The resulting cross link is of great significance, since it is highly stable and also resistant to mechanical and proteolytic degradation.

Microbial Transglutaminase Activity Assay
Assay principle The MICROBIAL TRANSGLUTAMINASE ASSAY KIT uses Z-Gln-Gly as the amine acceptor substrate and hydroxylamine as amine donor. In the presence of MTG hydoxylamine is incorporated into Z-Gln-Gly to form Z-glutamylhxdroxamate-glycine which develops a colored complex with iron (III) detectable at 525 nm.
Reagents in the kit (A1) ACTIVITY REAGENT 1: lyophilized TRIS buffer pH 6.0 containing Z-Gln-Gly, hydroxylamine and reduced glutathione, 3 vials
(A2) ACTIVITY REAGENT 2: Hydroxylamine, 3 vials
(S) STOP REAGENT: Hydrochloric acid [4% v/v], Iron (III) chloride, 3 vials
(P1) MICROBIAL TRANSGLUTAMINASE (positive control): 3 vials
Equipment The MICROBIAL TRANSGLUTAMINASE ASSAY KIT can be used in standard spectrophotometers with polystyrene 1 mL cuvettes. Refer to the instructions of the manufacturer.
Intended use Determination of microbial transglutaminase activity (MTG). Kit is sufficient for 3 x 11 measurements.
Storage P1 has to be stored at -20°C (shipment is possible at 4 – 8°C).
A1, A2, S has to be stored at 4 – 8°C.
The unopened reagents are stable until the expiration date printed on the box.
Reference(s) Grossowicz et al., J. Biol. Chem. 1950, 187:111-125
Rickert et al., Protein Sci. 2015, accepted manuscript (DOI: 10.1002/pro.2833)

Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy